In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Qinghe ZengSchool of Biomedical Engineering and Science, Drexel University, Philadelphia, PA, USA.
Landon FlemmingSchool of Biomedical Engineering and Science, Drexel University, Philadelphia, PA, USA.
Yuanzhou ChenDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.ORCID 0009-0008-2518-5626 Thomas MazumderDepartment of Medicine and Parker Institute for Cancer Immunotherapy, University of California, San Francisco, CA, USA.
Heinz HammerlindlDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.ORCID 0000-0001-5119-9791 Greg M AllenCell Design Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.ORCID 0000-0002-0032-8140 Ricardo AlmeidaCell Design Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.ORCID 0000-0002-3755-0669 Jasper Z WilliamsCell Design Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.ORCID 0000-0003-1578-2247 Rogelio A Hernández-LópezCell Design Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.ORCID 0000-0003-3968-4908 Ania-Ariadna BaeticaDepartment of Mechanical Engineering and Mechanics, Drexel University, Philadelphia, PA, USA.
Sara E MeyerDepartment of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Joseph A FraiettaCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-7900-8993 Justin EyquemDepartment of Microbiology and Immunology, University of California, San Francisco, CA, USA.ORCID 0000-0001-8262-1190 Chun J YeDepartment of Microbiology and Immunology, University of California, San Francisco, CA, USA.ORCID 0000-0001-6560-3783 Wendell A LimCell Design Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.ORCID 0000-0003-4052-8056 Tejal A DesaiDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA. tejal_desai@brown.edu.ORCID 0000-0003-3409-9208 Xiao HuangSchool of Biomedical Engineering and Science, Drexel University, Philadelphia, PA, USA. xh324@drexel.edu.ORCID 0000-0001-7733-9094 Funding
User-control and safetyU54CA244438 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A · 2019 to 2022
$7.8MDrexel University Startup fundNCI NIH HHS U54 CA244438U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) 1U54CA244438Wallace H. Coulter Foundation (WHCF) Coulter-Drexel Translational Research Partnership
6 · The paper itselfAbstract
T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without genetic rewiring are lacking. Here, we engineer CAREp, programmable DNA-scaffolded PLGA microparticles displaying CAR-targeting antigens and CD28-costimulatory antibodies, to repeatedly stimulate human CD8
Indexed as
CD8-Positive T-LymphocytesImmunotherapy, AdoptiveReceptors, Chimeric AntigenCD28 AntigensCell ProliferationErbB ReceptorsHumansLymphocyte ActivationMitochondriaPolylactic Acid-Polyglycolic Acid CopolymerSignal TransductionCD28 AntigensErbB ReceptorsPolylactic Acid-Polyglycolic Acid CopolymerReceptors, Chimeric Antigen
Identifiers
PMID42844241
PMCPMC13645755
What OpenQuestion holds
Textmetadata
Read underepoch 390